AMGN Stock Chart & Fundamental Analysis

Interactive Chart

About Amgen Inc.

Name

Amgen Inc.

CEO

Robert A. Bradway

Website

www.amgen.com

Industry

Healthcare

Year Founded

1980

Employees

28,000

Amgen Inc. develops, manufactures, and delivers human medicines as a large-cap biotechnology and biopharmaceutical company listed on NASDAQ as AMGN. Its portfolio spans inflammation, cancer and blood disorders, bone health, cardiovascular disease, kidney-related care, and neuroscience, and it generated $36.7 billion of revenue in FY2025.

Analyst Ratings

Consensus Recommendation

Buy5

Hold0

Sell2

Fundamentals & Financials

Revenue (TTM)

$37.2B

Net Income (TTM)

$7.8B

EPS (TTM)

$14.48

ROA (TTM)

8.43%

Current Ratio

1.26

Dividend Yield

0.71%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q1 FY2026	Q4 FY2025	Q3 FY2025
Revenue	$8,618M	$9,896M	$9,557M
Cost of Sales	$2,744M	$1,790M	$3,082M
Gross Profit	$5,874M	$8,106M	$6,475M
Operating Income	$2,666M	$3,942M	$2,526M
Net Income	$1,819M	$1,333M	$3,216M
EPS	$3.37	$2.47	$5.98

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

Amgen Inc.'s Technical Indicators Summary

AMGN presents a neutral technical posture driven by mixed momentum and a lack of clear trend strength. Price sits above recent short- and medium-term averages and well above the 200-day, indicating underlying longer-term support, while RSI and stochastics are overbought and MACD remains positive, producing conflicting signals. ADX is low so directional conviction is limited, ATR is moderate, and OBV shows accumulation which counters the overbought breadth. The pivot is below the market and provides immediate support. Technical takeaway: Neutral — upward bias exists but mixed momentum and weak trend strength temper the outlook.

Buy

5 signals

Neutral

0 signals

Sell

2 signals

Overall: Neutral0% Neutral signals

Indicator	Value	Signal	Explanation
RSI (14)	70.85	Sell	RSI (70.85) > 70, indicating overbought conditions.
Stochastic %K (14, 3, 3)	95.08	Sell	Stochastic (95.08) > 80, indicating overbought.
CCI (20)	208.62	Buy	CCI (208.62) > 100, indicating strong upward momentum.
WPR (14)	-2.43	Sell	Williams %R (-2.43) > -20, indicating overbought.
Momentum (10)	32.49	Buy	Momentum (32.49) is positive.
MFI	52.16	Neutral	MFI (52.16) is neutral.
MACD Level (12, 26)	6.56	Buy	Confirmed uptrend: MACD (6.56) is positive and above its signal line (4.25).
Bollinger Bands	$333.06 - $369.19	Sell	Price ($374.15) is above the upper band ($369.19).
ATR (14)	$8.53 (2.28%)	Neutral	Moderate Volatility (2.28%).
ADX (14)	14.34	Neutral	Weak or consolidating trend (ADX < 25). ADX(14.34), +DI(32.29), -DI(16.20)
OBV	62,382,310	Buy	Bullish volume pressure: OBV is above its 20-day SMA. OBV(62,382,310), 20D-SMA-OBV(57,250,478)
Classic Pivot Point	$361.07	Buy	Price ($374.15) has broken above resistance R1 ($364.26) — bullish breakout potential.
Fibonacci Pivot Point	$361.07	Buy	Price ($374.15) has broken above resistance R1 ($363.41) — bullish breakout potential.
Simple Moving Averages	$335.34 - $355.01(5 indicators)	Buy	SMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key SMA averages.
Exponential Moving Averages	$330.68 - $358.24(5 indicators)	Buy	EMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

The day concluded with AMGN retaining the 3.55% gap it started with from yesterday. By the close, sector strength was clear, with a 2.65% gain underpinning risk appetite. AMGN held its gap as sector strength and risk appetite supported the stock, even as Fulton Bank trimmed its AMGN stake.

Trading Volume

vs S&P 500 Today

Strong Outperformance

+13.15%

52-Week Position

Upper range

85.9%

Updated: July 2, 2026 at 20:17 UTC